Work

Reducing α-Synuclein in Human CSF; An Evaluation of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MEDI1341, an α-Synuclein-specific antibody, in Healthy Volunteers and Parkinson’s Disease Patients (P1-11.007)

Year: 2023

Type: article

Source: Neurology

DOI: 10.1212/wnl.0000000000202579

Authors: Craig Shering, Michael Pomfret, Robert kubiak, Isabelle Pouliquen, Wei Yin, Arthur Simen, Elena Ratti, Michael Perkinton, Keith Tan, Iain Chessell, Thor Ostenfeld

Institutions: AstraZeneca (United States), AstraZeneca (United Kingdom)

Language: English

Topic: Parkinson's Disease Mechanisms and Treatments

Subfield: Neurology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4367304032

FWCI: 1.621

Cites:

Cited by: 11

Related to: 10